We are improving the lives of people suffering from mental illness and substance use disorders
What we do
HQ & Pipeline
Digital Therapeutics
Discover our story
Key News
NOVEMBER 3, 2022
Orexo Interim Report Q3 2022
NOVEMBER 3, 2022
Presentation of the Q3 2022 Interim Report - November 3 at 2 pm CET
OCTOBER 28, 2022
Last patient enrolled in the clinical MODIA® study
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).
MODIA® - our digital therapy for opioid use disorder
- to be used along with pharmaceuticals
- 180 days treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. more than 430 patients
News Flow
Regulatory Press Releases
Press Releases & News
Orexo announces last patient enrolled in pivotal study evaluating the efficacy of MODIA® in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo appoints Edward Kim, M.D., as new Chief Medical Officer
Invitation to presentation of the Q3 Interim Report, on November 3 at 2 pm CET
Orexo’s partner Gesynta Pharma prepares phase 2 study for OX-MPI aiming to develop an innovative treatment for endometriosis
Orexo Social
@OrexoABpubl
6 December 2022
Epinephrine is the 1st-line treatment for #anaphylaxis. If you’re someone who can’t go anywhere without your auto-i… https://t.co/7oEtTBjgRp
@OrexoABpubl
30 November 2022
View the presentation held at @aktiespararna Stora Aktiedagen yesterday, focusing on ▶ Our core mission ▶ The comm… https://t.co/M0bwTfPSmN
@OrexoABpubl
29 November 2022
Today at 12-12.30 pm our CEO Nikolaj Sørensen will present @aktiespararna Stora Aktiedagen in Stockholm, Sweden. Af… https://t.co/6qbqXDJ9ZG
Financial Snapshot
Group net revenues
612.3 MSEK
LTM1
Group EBITDA
-110.6 MSEK
LTM1
US Pharma segment EBIT
304.5 MSEK
LTM1
Cash position
444 MSEK
Q3 2022
1 Last Twelve Months, Q421-Q322, for more information about financial development Link